ClinicaliQ Trial Snapshot
- A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation — Active Not Recruiting • Phase III • Oncology • NCT03383458.
- Nivolumab versus placebo to prevent cancer recurrence in patients with liver cancer after surgery or ablation.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence Conditions: Hepatocellular Carcinoma, Liver Cancer Interventions: Nivolumab, Placebo Lead Sponsor: Bristol-Myers Squibb Planned Enrollment: 545 participants